Search

Your search keyword '"Eliaschewitz, Freddy G"' showing total 35 results

Search Constraints

Start Over You searched for: Author "Eliaschewitz, Freddy G" Remove constraint Author: "Eliaschewitz, Freddy G"
35 results on '"Eliaschewitz, Freddy G"'

Search Results

2. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

3. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

5. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

11. Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China : A 30‐week, double‐blind, phase 3a, randomized trial

13. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

14. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

15. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

16. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

17. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

18. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

19. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

20. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

23. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

24. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial

25. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

26. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

28. Islet vs. pancreas transplantation in Brazil: Defining criteria for pancreas allocation decision

32. Custo-efetividade e impacto orçamentário da saxagliptina como terapia adicional à metformina para o tratamento do diabetes mellitustipo 2 no sistema de saúde suplementar do Brasil

34. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

35. Starting glargine in insulin-naïve type 2 diabetic patients based on body mass index is safe.

Catalog

Books, media, physical & digital resources